Evidence map›Paper›PMID 35392221›Full record

ArticleFrontiers in oncology2022

A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells.

Da-Lai Xu, Yuan-Qing He, Bin Xiao, Yuan Si, Jian Shi, Xue-Ang Liu, Lei Tian, Qian Ren, Ya-Song Wu, Yi Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Challenges and new technologies in adoptive cell therapy.Journal of hematology & oncology · 2023
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Da-Lai XuPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yuan-Qing HeLaboratory Animal Research Center, Jiangsu University, Zhenjiang, China.
Bin XiaoPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yuan SiResearch & Development Department, Timmune Biotech Inc., Tianjin, China.
Jian ShiPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xue-Ang LiuPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lei TianPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qian RenLaboratory Animal Research Center, Jiangsu University, Zhenjiang, China.
Ya-Song WuResearch & Development Department, Timmune Biotech Inc., Tianjin, China.
Yi ZhuPancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and lethal malignancy with a limited response to current therapies. Novel and effective treatment is urgently needed. Herein, a chimeric antigen receptor (CAR)-NK92 cell line, with an interleukin (IL)-15Rα-sushi/IL-15 complex and a Programmed cell death-1(PD1) signal inverter was constructed and named SP (

Indexed as

adoptive immunotherapyChimeric antigen receptor (CAR)IL-15IL-15Rα-sushipancreatic ductal adenocarcinomaprogrammed cell death ligand 1 (PD-L1)

Identifiers

PMID35392221
PMCPMC8980464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.